Hoth Therapeutics Inc (NASDAQ:HOTH) stock continues to trade higher in the pre-market session on Monday after gaining 5% last week.
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
- Hoth Therapeutics announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.
- BioLexa has been administered twice per day for 14 days to the first ten subjects within Cohort 1; The interim safety review indicates that BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed.
“Today’s announcement represents a significant milestone for Hoth,” stated Robb Knie, CEO of Hoth Therapeutics. “We are very pleased by the Cohort 1 results and are proceeding as planned with submission and enrollment for Cohort 2 with atopic dermatitis patients later this year.”
As of 8:36, HOTH stock jumped 3.77% to $1.65. So far more than 211k shares have exchanged hands.